Literature DB >> 11104617

Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.

A van Dalen1, J Favier, A Burges, U Hasholzner, H W de Bruijn, D Dobler-Girdziunaite, V H Dombi, D Fink, M Giai, P McGing, A Harlozinska, C Kainz, J Markowska, R Molina, C Sturgeon, A Bowman, R Einarsson.   

Abstract

OBJECTIVE: To evaluate the prognostic significance of and predictive value for survival of CA 125 and TPS levels after three chemotherapy courses in ovarian cancer patients.
METHODS: We analyzed in a prospective multicenter study the 1- and 2-year overall survival (OS) in ovarian carcinoma patients. The prognostic significance of CA 125 and TPS levels above the discrimination value (25 kU/L and 100 U/L, respectively) was examined by univariate and multivariate analyses.
RESULTS: Of the 213 cases included, 64 patients were staged as FIGO I + II and 149 patients were staged as FIGO III + IV. Tumor marker levels in stage I + II were not correlated with survival. However, stage III and IV patients with elevated levels of CA 125 or TPS after three chemotherapy courses had a worse 2-year OS (69% vs 26%, P < 0.0001 and 57% vs 20%, P < 0.0001, respectively) than patients with normal levels of the markers. In univariate analysis the result of operation (staging laparatomy and partial debulking) and advanced FIGO stage (IV) were also adverse prognostic factors. Independent factors predictive of low 2-year OS by multivariate analysis were staging laparotomy, TPS elevated, and CA 125 elevated. The only factors predictive of low 1-year OS were TPS elevated and staging laparotomy.
CONCLUSIONS: Ovarian cancer patients with elevated CA 125 levels after three chemotherapy courses have a poor prognosis. However, the prognostic accuracy can be significantly increased by the parallel determination of serum TPS. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104617     DOI: 10.1006/gyno.2000.5982

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

1.  Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.

Authors:  Tugan Bese; Merve Barbaros; Elif Baykara; Onur Guralp; Salih Cengiz; Fuat Demirkiran; Cevdet Sanioglu; Macit Arvas
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

2.  3-cinnamoyl-4-hydroxy-6-methyl-2H-pyran-2-one (CHP) inhibits human ovarian cell proliferation by inducing apoptosis.

Authors:  Qiong-Yu Lan; Que-Ling Liu; Jing Cai; An-Wen Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Prognosis and conditional disease-free survival among patients with ovarian cancer.

Authors:  Michelle L Kurta; Robert P Edwards; Kirsten B Moysich; Kathleen McDonough; Marnie Bertolet; Joel L Weissfeld; Janet M Catov; Francesmary Modugno; Clareann H Bunker; Roberta B Ness; Brenda Diergaarde
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

4.  Development and characterization of three novel monoclonal antibodies against CA-125.

Authors:  Tatiana Michurina; Maxim Kerzhner; Boris Klimovich
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-10

5.  Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.

Authors:  Digant Gupta; Carolyn A Lammersfeld; Pankaj G Vashi; Donald P Braun
Journal:  J Ovarian Res       Date:  2010-10-12       Impact factor: 4.234

6.  Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?

Authors:  Roberto Angioli; Stella Capriglione; Alessia Aloisi; Federica Guzzo; Daniela Luvero; Andrea Miranda; Patrizio Damiani; Roberto Montera; Corrado Terranova; Francesco Plotti
Journal:  Tumour Biol       Date:  2014-04-21

Review 7.  Molecular and clinical implementations of ovarian cancer mouse avatar models.

Authors:  Amira A Zayed; Sumithra J Mandrekar; Paul Haluska
Journal:  Chin Clin Oncol       Date:  2015-09

Review 8.  HE4 as a biomarker for ovarian and endometrial cancer management.

Authors:  Jinping Li; Sean Dowdy; Tracy Tipton; Karl Podratz; Wei-Guo Lu; Xing Xie; Shi-Wen Jiang
Journal:  Expert Rev Mol Diagn       Date:  2009-09       Impact factor: 5.225

9.  Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer.

Authors:  Sharmila Upadhya; Subramanya Upadhya; D M Vasudevan
Journal:  Indian J Clin Biochem       Date:  2003-01

10.  Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  J Ovarian Res       Date:  2009-10-09       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.